article thumbnail

Grand Rounds March 21, 2025: Generative Artificial Intelligence in Clinical Trials: A Driver of Efficiency and Democratization of Care (Alexander J. “AJ” Blood, MD, MSc)

Rethinking Clinical Trials

Its becoming more expensive and time-consuming to move a drug from the clinical trial stage to approval. Patient recruitment is the leading driver of costs in clinical trials, and 55% of trials that fail to complete cite low accrual rate as the reason for study termination.

article thumbnail

Samsung Biologics, GreenLight conclude Covid-19 vaccine engineering run

Pharmaceutical Technology

Samsung Biologics and GreenLight Biosciences have completed the initial commercial-scale engineering run for their messenger ribonucleic acid (mRNA) Covid-19 vaccine under their manufacturing collaboration. Following the demonstration at Samsung, the clinical trial of GreenLight’s Covid-19 booster vaccine is anticipated to commence this year.

Engineer 262
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Providing the Blueprint for Gen AI Adoption in Clinical Trials

ACRP blog

It’s even being used to review investigator invoices and automate financial reconciliations—a monthly headache every contract research organization, sponsor, and clinical trials operator will be more than happy to resign to machines. MGI puts the value of this contribution to clinical development at $15 billion to $25 b illion.

article thumbnail

June 27, 2022: Special Edition of Contemporary Clinical Trials Offers New Perspectives on Pragmatic and Virtual Clinical Trials

Rethinking Clinical Trials

A special series of articles addressing pragmatic and virtual trials appears this week in the journal Contemporary Clinical Trials and offers practical approaches to the many challenges clinical trials face. The special issue can be found on the Contemporary Clinical Trials website.

article thumbnail

BlueRock Advances Bemdaneprocel Cell Therapy to Phase III Trial for Parkinson’s Disease

XTalks

BlueRock Therapeutics, a subsidiary of Bayer AG, is making waves in the treatment of Parkinsons disease by advancing its investigational cell therapy, bemdaneprocel, to a Phase III clinical trial. These stem cells are engineered to develop into dopamine-producing neurons, which are progressively lost in Parkinsons disease.

Trials 104
article thumbnail

Ginkgo buys StrideBio’s AAV discovery and engineering platform assets

Pharmaceutical Technology

Ginkgo Bioworks has strengthened its end-to-end R&D capabilities in gene therapy with the purchase of adeno-associated virus (AAV) capsid discovery and engineering assets from StrideBio, for an undisclosed sum. AAV is used in hundreds of active clinical trials, and is described as the preferred viral vector for gene therapy.

Engineer 130
article thumbnail

Not A Placebo: Study Finds Meditation Offers Genuine Pain Relief

AuroBlog - Aurous Healthcare Clinical Trials blog

(Engin Akyurt/Pixabay) If you’re in a lot of pain, being told to take deep breaths and accept the sensations in your body might not feel particularly comforting.

Engineer 244